NCT02357888View on ClinicalTrials.gov

Assessment of V0018 2.5 mg Effect on Craving

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Healthy Highly Dependant Smokers
Interventions
DRUG

V0018

Oromucosal - Single dose

DRUG

Placebo

Oromucosal - Single dose

Trial Locations (1)

Unknown

Gières

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT02357888 - Assessment of V0018 2.5 mg Effect on Craving | Biotech Hunter | Biotech Hunter